Clipperton acted as financial advisor to the majority shareholder of padoa, Kamet Ventures, on the investment by Thoma Bravo in padoa. The investment is designed to accelerate padoa’s mission to improve the health of millions of people and enable padoa to further invest in AI capabilities, customer service, international expansion, particularly in the DACH region, and product innovation. The investment is being made through Thoma Bravo’s dedicated European fund, with significant participation from padoa’s co-founders and existing shareholders, Five Arrows, the alternative assets arm of Rothschild & Co, and Kamet Ventures.
